Clinical Studies at Center For Sight

Center For Sight is committed to advancing the state of the art in eye care and we believe that clinical trials play a crucial role in that regard. In order to help identify new technologies, medications and treatments, we have established a full-time Clinical Research Department. Since its inception, our center has been selected to participate in numerous FDA-monitored clinical trials, many of which have gained FDA approval.

Our goal when offering any clinical trial is to provide better outcomes. Patients who participate in our studies gain access to promising treatments that are unavailable to the general public. Clinical trials allow the use of newly developed technology or treatments in a controlled setting under close observation.

If you fit the criteria for one of our open studies, please contact our Clinical Research Department at 941.373.6211 to learn more.


Current Studies

The following studies are currently in progress.

Glaucoma: Dr. Joshua Kim, Principal Investigator

OPEN ENROLLMENT – S088 – The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM

Inclusion Criteria:

  • Male and females 18 years of age or older
  • Diagnosed with primary open-angle glaucoma or ocular hypertension

Exclusion Criteria:

  • Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle glaucoma
  • Ocular hypertension

 

OPEN ENROLLMENT – GC-010 – TRAVOPROST INTRAOCULAR IMPLANT CLINICAL STUDY – If you’ve been told by your doctor that you have glaucoma or high eye pressure, you may be able to participate in a clinical study of the Travoprost Intraocular Implant.

Inclusion Criteria:

  • Be 18 years of age or older
  • Meet all other study-related criteria

Participants receive:

  • Thorough screening evaluation of your eye health
  • Follow-up visits for up to three years
  • Reimbursement for costs related to time and travel

HOW YOU CAN PARTICIPATE

An intraocular implant containing a slowly releasing travoprost medication will be placed in your eye through a tiny opening in the cornea.

Ask your eye doctor if you are a candidate for the Travoprost Intraocular Implant clinical study.
To learn more about the Travoprost Intraocular Implant clinical study visit www.GlaukosClinicalTrials.com

Caution: New Drug—Limited by Federal (or United States) law to investigational use.

 

OPEN ENROLLMENT – 192024-092 – This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Inclusion Criteria:

  • Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.

Exclusion Criteria:

  • Previous enrollment in another Allergan Bimatoprost SR Study
  • Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
  • Anticipated need for laser eye surgery within the first 52 weeks of the study duration
  • History of glaucoma surgery

 

 

ENROLLMENT COMPLETED – GC-007 – Evaluate the safety and efficacy of the Glaukos® Suprachoroidal Stent Model G3 in conjunction with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate primary open-angle glaucoma.

Inclusion Criteria:

  • Mild to moderate primary open-angle glaucoma
  • Currently treated with ocular hypotensive medication
  • Pseudoexfoliative and pigmentary glaucoma are acceptable diagnoses
  • Subject scheduled to undergo cataract surgery

Exclusion Criteria:

  • Primary angle-closure glaucoma; or secondary angle closure glaucoma, including neovascular glaucoma
  • Retrobulbar tumor, thyroid eye disease, Sturge-Weber syndrome or any other type of condition that may cause elevated episcleral venous pressure

 

ENROLLMENT COMPLETED – GC-008 – A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery

Inclusion Criteria:

  • Mild to moderate open-angle glaucoma
  • Characteristics consistent with mild/moderate glaucoma
  • Use of one (1) to three (3) medications at time of screening exam

Exclusion Criteria:

  • Pigmentary or pseudoexfoliative glaucoma
  • Prior incisional glaucoma surgery

 

ENROLLMENT COMPLETED – GC-009 – Prospective, Randomized Phase II Study Comparing Two Elution Rates Of Glaukos® Travoprost Intraocular Implants To Timolol Maleeate Ophthalmic Solution, USP, 0.5%

Inclusion Criteria:

  • Mild to moderate open-angle glaucoma/ Ocular Hypertension
  • Characteristics consistent with mild/moderate glaucoma
  • Use of one (0) to three (3) medications at time of screening exam

Exclusion Criteria:

  • Pigmentary or pseudoexfoliative glaucoma
  • Prior incisional glaucoma surgery